Form D · Pharmaceuticals
Oncolinx Pharmaceuticals, LLC
Boston, MA · CIK 0001627422
Offering snapshot reported Dec 30, 2014 · SEC filing
- Reported sold
- $350K Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 31, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2014 | Initial | $350,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-231043
Source: Form D, filed Dec 30, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Riley Ennis | Director, Executive, Promoter |
| Sourav Sinha | Director, Executive, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Mass Challenge, Attn: Oncolinx 21 Drydock Avenue, 6th Floor
Boston, MA, 02210
Boston, MA, 02210